Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.

Autor: Hanchard J; Aphaia Pharma AG, Zug, Switzerland.; Department of Physiology, University of Toronto, Toronto, ON, Canada.; Toronto Centre for Microvascular Medicine at The Ted Rogers Centre for Heart Research Translational Biology and Engineering Program, University of Toronto, Toronto, ON, Canada., Capó-Vélez CM; Aphaia Pharma AG, Zug, Switzerland., Deusch K; Aphaia Pharma AG, Zug, Switzerland., Lidington D; Aphaia Pharma AG, Zug, Switzerland.; Department of Physiology, University of Toronto, Toronto, ON, Canada.; Toronto Centre for Microvascular Medicine at The Ted Rogers Centre for Heart Research Translational Biology and Engineering Program, University of Toronto, Toronto, ON, Canada., Bolz SS; Aphaia Pharma AG, Zug, Switzerland.; Department of Physiology, University of Toronto, Toronto, ON, Canada.; Toronto Centre for Microvascular Medicine at The Ted Rogers Centre for Heart Research Translational Biology and Engineering Program, University of Toronto, Toronto, ON, Canada.
Jazyk: angličtina
Zdroj: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2020 Sep 30; Vol. 11, pp. 583006. Date of Electronic Publication: 2020 Sep 30 (Print Publication: 2020).
DOI: 10.3389/fendo.2020.583006
Abstrakt: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its clinical manifestation (COVID-19; coronavirus disease 2019) have caused a worldwide health crisis. Disruption of epithelial and endothelial barriers is a key clinical turning point that differentiates patients who are likely to develop severe COVID-19 outcomes: it marks a significant escalation in respiratory symptoms, loss of viral containment and a progression toward multi-organ dysfunction. These barrier mechanisms are independently compromised by known COVID-19 risk factors, including diabetes, obesity and aging: thus, a synergism between these underlying conditions and SARS-CoV-2 mechanisms may explain why these risk factors correlate with more severe outcomes. This review examines the key cellular mechanisms that SARS-CoV-2 and its underlying risk factors utilize to disrupt barrier function. As an outlook, we propose that glucagon-like peptide 1 (GLP-1) may be a therapeutic intervention that can slow COVID-19 progression and improve clinical outcome following SARS-CoV-2 infection. GLP-1 signaling activates barrier-promoting processes that directly oppose the pro-inflammatory mechanisms commandeered by SARS-CoV-2 and its underlying risk factors.
(Copyright © 2020 Hanchard, Capó-Vélez, Deusch, Lidington and Bolz.)
Databáze: MEDLINE